Cardiovascular morbidity and mortality as a result of inhaled tobacco products continues to be a global healthcare crisis, particularly in low-and middle-income nations lacking the infrastructure to develop and implement effective public health policies limiting tobacco use. Following initiation of public awareness campaigns 50 years ago in the United States, considerable success has been achieved in reducing the prevalence of cigarette smoking and exposure to secondhand smoke. However, there has been a slowing of cessation rates in the United States during recent years, possibly caused by high residual addiction or fatigue from cessation messaging. Furthermore, tobacco products have continued to evolve faster than the scientific understanding of their biological effects. This review considers selected updates on the genetics and epigenetics of smoking behavior and associated cardiovascular risk, mechanisms of atherogenesis and thrombosis, clinical effects of smoking and benefits of cessation, and potential impact of electronic cigarettes on cardiovascular health. (J Am Coll Cardiol 2015;66:1378-91)
I
nhaled tobacco products are highly engineered, pleasurable, and rapid delivery systems for nicotine, a highly addictive substance, in addition to numerous harmful toxicants and carcinogens (1, 2) . When tobacco is burned, a complex chemical mixture of more than 7,000 compounds is produced, many of which are causally associated with premature deaths and diseases affecting nearly every organ system in the body (2-4). Cigarette smoking is the predominant form of tobacco exposure throughout the world (5, 6 ). Global estimates demonstrate a significant reduction in the prevalence of daily smoking in both men and women between 1980 and 2012 (7, 8) . However, the total number of smokers worldwide has increased during this period, from approximately 721 million to 967 million, largely because of population growth. The burden of disease attributable to cigarette smoke exposure (CSE) and secondhand smoke (SHS) is substantial, causing 6.3 million deaths annually and 6.3% of disabilityadjusted life-years (8) . In Western Europe and highincome North America, CSE and SHS are the leading risk factors for morbidity and mortality, and globally only high blood pressure is associated with a higher burden of disease.
One-third of deaths from CSE are secondary to cardiovascular disease (CVD) and 11.1% of these deaths occur in people with exposed to SHS (9) .
Extensive epidemiological research on SHS spanning several decades supports a strong causal relationship with a 25% to 30% increase in coronary heart disease (CHD) (10) (11) (12) . CSE has a nonlinear dose effect on CVD and risk is increased at all levels of CSE, even among persons smoking fewer than 5 cigarettes per day and with exposure to SHS (13, 14) . Evidence also suggests that the cardiovascular effects of CSE may have a low threshold effect, with a marked increase in risk at even low levels of exposure ( Figure 1 Surgeon General (18) . The authors' purpose is to reinvigorate commitment to advance the scientific understanding of smoking behavior and the cardiovascular effects of tobacco products and newer forms of nicotine exposure, to encourage advocacy efforts to more broadly implement smoke-free policies, and to make cessation counseling a clinical imperative for every patient.
GENETICS AND EPIGENETICS OF TOBACCO-RELATED CVDs
Genomic and epigenomic studies have provided important insights into the risk for initiation of tobacco use, the intensity of smoking behavior, mechanisms of CSE-induced atherogenesis, and evidence to support a causal association between CSE and CVD risk ( Table 1 ).
In the recent Tobacco and Genetic Consortium meta-analysis of genome-wide association studies, several common polymorphisms were found to be robustly associated with smoking behavior (19). The strongest evidence for association was a synonymous Morris et al. (24, 25) . Together, these data suggest that exposure to tobacco smoking may be causally associated with an increased risk of both all-cause and cardiovascular mortality, and with an increased risk of CVD events. These data must be interpreted with caution, however, because both BDNF SNPs studied are also associated with increased body mass index (22, 24) . Because of the pleiotropic effect of these SNPs, it is not possible using the available evidence to determine how much of the association between these BDNF SNPs and the risk of CVD and totality mortality is mediated by smoking and how much, if any, may be mediated by their effect on body mass index.
S E P T E M B E R
CSE may also cause CVD through epigenetic effects. The best understood epigenetic effect is DNA methylation, a covalent modification that occurs predominantly at cytosines followed by guanines (CpG dinucleotides) (26) . CSE is one of the most powerful environmental modifiers of DNA methylation (27) , and is strongly associated with a pattern of DNA Morris et al.
Cardiovascular Effects of Tobacco S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 7 8 -9 1 methylation at distinct loci that can reliably distinguish between smokers and nonsmokers (18, 26, (28) (29) (30) .
In recent epigenome-wide association studies, CSE was strongly associated with hypomethylation of a CpG site in the protease-activated receptor 4 gene (F2RL3). *p value less than the threshold for genome-wide significance (p < 5 Â 10 -8 ).
SNP ¼ single-nucleotide polymorphism.
Morris et al. Morris et al. These structural changes result in decreased platelet membrane fluidity and may cause an increase in platelet activation and aggregation (77) .
Plasma fibrinogen levels of smokers are consistently higher than levels in nonsmokers (78) . Factor XIII covalently cross-links and stabilizes the fibrin clot and levels of the A subunit of factor XIII are significantly increased in smokers (79) . CSE is associated with shortening of the time for fibrin clot formation, augmented clot strength, and an alteration in fibrin architecture (80) . Fibrin clots in smokers have thinner fibers on electron microscopy, higher clot turbidity, higher fibrin fiber density, and more uniform fiber distribution.
CSE is associated with an increase in tissue factor (TF)-containing microparticles in the circulation and in the number of tissue macrophages, the predominant source of TF in atherosclerotic plaques (81, 82) . CSE reduces the expression of TF inhibitor by the endothelium and increases circulating TF activity (83, 84) . A strong association between the number of cigarettes smoked per day and circulating TF activity is indicative of a possible dose-response relationship.
TF pathway inhibitor-1 is a potent regulator of TF factor VIIa-dependent activation of the TF pathway.
Smokers have a relative increase of the TF/TF pathway inhibitor-1 ratio and an increase in thrombotic potential (80) .
CSE is associated with reduced fibrinolytic capacity and can adversely influence the fibrinolytic balance in the circulation (85) . CSE is associated with impaired coronary release of active tissue-type plasminogen activator and a dose-related increase in plasma plasminogen activator inhibitor-1 antigen and activity (86) .
CLINICAL EFFECTS OF CSE
Clinical manifestations of CSE can be observed throughout the spectrum of CVD. CSE increases myocardial oxygen demand, resulting in shorter time to the onset of angina (87) . The risk of developing CHD and myocardial infarction (MI) is several-fold higher in cigarette smokers compared with nonsmokers (88, 89) . Compared with lifelong nonsmokers, both prior smoking and current smoking increase the risk of developing heart failure by as much as 33% to 93% (90,91). The risk does not seem to be limited to smoking tobacco products, because moist snuff has also been associated with a higher risk of heart failure (92). Among patients with heart failure, continued smoking increases the risk of multiple hospital admissions (OR: 1.82) (93).
CSE is the most important risk factor for the development and severity of peripheral arterial disease. It increases the risk of peripheral arterial disease by several-fold and is a more influential risk factor for peripheral arterial disease than for CHD (94, 95) .
Abdominal aortic aneurysm (AAA) is the most common form of CSE-related aortic disease and the OR for development of AAA is higher than that for CHD (96, 97) . CSE has been associated with an increased hazard for AAA incidence among women and men who were current smokers with more than 20 packyears of exposure (hazard ratio: 10.97 and 6.55, respectively) (98) .
The association between stroke and CSE has been demonstrated in multiple studies, in men and Several observational studies have reported on the incidence of AF in smokers. In the Rotterdam study, the incidence of AF in current and previous smokers was higher than in nonsmokers (51% and 49% increases, respectively), and was not affected by adjustment for AF risk factors (132) . The incidence of AF was also higher in current and previous smokers compared with nonsmokers in the Atherosclerosis Risk in Communities study (133). Overall, smoking doubled the incidence of AF. The risk was dosedependent and the highest smoking tertile was associated with the highest risk of AF. Smoking also increased the incidence of AF in the Manitoba FollowUp Study (134) , whereas in the Framingham study, smoking was associated with higher incidence of AF in women, but not in men (135) .
In a secondary analysis from MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II), the incidence of inappropriate shocks was 20% in current smokers, 14% in ex-smokers, and 11% for never-smokers (p ¼ 0.03 for the trend) (124, 136) . CSE also increased the risk of appropriate implantable Morris et al.
CARDIOVASCULAR EFFECTS OF ECs

S E P T E M B E R
Cardiovascular Effects of Tobacco and enhance angiogenesis, effects that raise concerns about the role of nicotine in promoting the acceleration of atherosclerotic disease (42, 43) . Nicotine in ECs has been shown to increase heart rate after overnight abstinence (150) . Short-term EC use was reported to result in a small increase in diastolic blood pressure, but unlike cigarette smoking, resulted in no diastolic dysfunction and no reduction in coronary flow velocity reserve, although the devices were low-nicotine delivery devices (151, 152) . Electronic cigarettes consist of a cartridge containing liquid (propylene glycol, glycerine, nicotine, and flavorings), a heating element (atomizer), a battery, and a microchip. Cigalikes emulate the look of real cigarettes, although they may be slightly bigger and heavier. Secondgeneration electronic cigarettes resemble a pen, are bigger and heavier, and have a larger battery capacity. These allow the user to customize the e-liquid by varying flavors and nicotine strengths. Third-generation devices include mechanical mods and variable voltage devices, using larger batteries that can hold larger tanks of e-liquid. Courtesy of Dr. Gideon St. Helen, University of California-San Francisco.
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the short-term case fatality rate was increased in snus users (OR: 1.28; 95% CI: 0.99 to 1.68). A recent study did find that quitting smokeless tobacco use after a MI substantially reduces mortality, suggesting a harmful effect in people with CHD (158) . Thus, although adverse health effects of nicotine from ECs cannot be ignored, they are likely to be much less than those of CSE, which exposes the smoker to both nicotine and to thousands of combustion-generated toxins.
CARBONYLS. Thermal degradation of propylene glycol can generate propylene oxide, which is classi- PARTICULATES. ECs generate an aerosol consisting of fine and ultrafine particles in a gas phase. In a few reports involving a limited number of devices and liquids, the particle number and size distribution of the mainstream aerosol generated by ECs was similar to that of conventional tobacco cigarettes (162, 163) .
The number of particles in EC aerosol is influenced by the liquid nicotine content and by puffing time, and higher levels of particles were generated by ECs 
